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Abstract
Background: Repeated injection of corticosterone (CORT) induces dysregulation in the hypothalamic-pituitary-adrenal
(HPA) axis, resulting in depression. We examined the effects of Angelica gigas extract (AGN) treatment in a rat model of
depressive and anxiety-like behaviors, induced by chronic CORT exposure.
Methods: Male rats received 10, 20, or 50 mg/kg AGN (i.p.) 30 min prior to a daily injection of CORT for 21 consecutive
days. Activation of the HPA axis in response to the repeated CORT injections was confirmed by measuring serum levels
of CORT and the expression of corticotropin-releasing factor in the hypothalamus.
Results: Daily AGN administration significantly reversed the depression and anxiety-like behavioral abnormalities. It also
blocked increases in tyrosine hydroxylase expression in the locus coeruleus, and suppressed the decreased expression
levels of brain-derived neurotrophic factor (BDNF) and its receptor TrkB mRNAs in the hippocampus.
Conclusions: These findings indicate that administration of AGN prior to high-dose exogenous CORT significantly
improved helpless behaviors, possibly by modulating the central noradrenergic system and regulation of BDNF
expression in rats. Thus, AGN may be a useful agent for the treatment or alleviation of psychiatric disorders associated
with depression and anxiety disorders.
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Background
Depression is a common psychiatric disorder that causes
problems for humans worldwide because of its substantial
association with disabilities; it can even be life-threatening
[1]. In recent years, chronic exposure to stressful life events
has become an established and important risk factor for the
development and maintenance of many psychological or
helpless conditions in humans including depression and
anxiety [2]. This has supported the notion that dysregula-
tion of the hypothalamic-pituitary-adrenal (HPA) axis may
be involved in the pathogenesis of psychologically related
disorders, such as depression [3]. Chronic stress results in
dysregulation of the HPA axis in the neuroendocrine sys-
tem, as evidenced by observations that elevated circulating
corticosterone (CORT) levels disrupt the circadian regula-
tion of CORT secretion and the glucocorticoid (GC)
receptor-negative feedback circuit [4]. This negative
feedback in the hippocampus is impaired in major depres-
sion patients, resulting in hyperactivity of the HPA axis and
increased levels of humeral corticosteroids [5, 6]. Thus, pa-
tients with Cushing’s disease or those undergoing long-
term pharmacotherapy with GC exhibit an extremely high
rate of depression [7]. Stimulation and sustained actions of
the HPA axis is attenuated via the negative feedback action
of circulating GC following exogenous CORT administra-
tion, and this is closely associated with the development of
psychosomatic disorders, which produce serious changes in
affective behavior that are indicative of, or consistent with,
depressive-like symptoms [8, 9]. Activation of the HPA axis
by high-dose CORT administration increases depression-
like behavior in rodents, as indicated by a significant
decrease in sucrose consumption [8], alterations in a
variety of neurotransmitters, and increases in immobility
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time of forced swimming test (FST) [10, 11]. However, this
can be significantly reversed by antidepressants and acu-
puncture treatment [12–14].
The dried radix of Angelica gigas, termed “Korean
Dang Gui”, and generally known as “Korean angelica”, is
a popular medicinal plant in Korea. The plant has been
used traditionally in the treatment of psychosomatic
diseases, such as depression via its hemogenic, health-
promoting activities, analgesic, and sedative activities
in Korean herbal prescriptions [15, 16]. It has multiple
pharmacological activities, including anticancer, anti-
bacterial, antiplatelet aggregation, antinematodal activities,
and antioxidant properties [15]. Additionally, several studies
have indicated that Angelica gigas demonstrated anxiolytic
and anti-inflammatory effects [17]. Recently, some studies
have shown that angelica essential oil exhibited anxiolytic-
like effects in three murine tests of anxiety [18], and
Japanese angelica root extract reversed stress-induced
decrease in pentobarbital sleep through central noradrener-
gic or GABAA receptors in mice [19]. Although a brief
report on the anti-inflammatory activity and anxiolytic-like
effects of Angelica gigas has been published [17, 18], it is
currently unknown whether Angelica gigas extract (AGN)
can improve the depression- and anxiety-like symptoms
induced by repeated CORT injections in rats.
The aim of the present study was to investigate the
medicinal impacts of AGN on chronic stress-induced
depression- and anxiety-related symptoms in an animal
model using behavioral and neurobiological methodolo-
gies. Using the forced swimming test (FST) and elevated
plus maze (EPM) test, the administration of AGN was
evaluated for its efficacy in alleviating depression- and
anxiety-like behavior in rats that were repeatedly exposed
to exogenous CORT. Additionally, the underlying neuro-
biological mechanism of these behaviors was investigated
through an evaluation of the central noradrenergic system
and the regulation of BDNF signaling via TrkB expression
in brains of rats following repeated CORTadministration.
Methods
Animals
Adult male Sprague-Dawley (SD) rats weighing 260-280 g
were obtained from Samtako Animal Co. (Seoul, Korea).
Animals were maintained on a 12-h light/dark cycle (lights
on at 7: 00 a.m., lights off at 7: 00 p.m.) under controlled
temperature (22 ± 2°C) and humidity (55 ± 15 %), and they
were given standard diet and water during the experi-
ments. The rats were housed in a limited access rodent
facility with up to five rats per polycarbonate cage. The
animal experiments were conducted in accordance with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals (NIH Publications No. 80-23),
revised in 1996, and were approved by the Kyung Hee
University Institutional Animal Care and Use Committee.
The animals were allowed 1 week to acclimatize them-
selves to the housing conditions before the beginning of
the experiments. The effects were made to minimize the
number and suffering of animals.
Preparations of methanol extract of Angelica gigas and
drugs
Dried roots of Angelica gigas was purchased from Jongdo
Pharmacy Co., Ltd. (Seoul, Korea). A voucher specimen of
Angelica gigas has been deposited at the herbarium located
at the College of Korean Medicine, Kyung Hee University
(No. KH-AG01 for AG). Two hundred grams of Angelica
gigas were cut into small pieces and extracted three times
with 2 L of 80 % methanol by sonication in a reflux
condenser for 24 h at room temperature (25 ± 2 °C).
The extracted solutions were combined, filtered through
Whatman No. 1 filter paper, and concentrated using a
rotary vacuum evaporator (EYELA CCA-110, Tokyo
Rikakikai Co., Tokyo, Japan) and dried with a freeze
dryer (EYELA FD-800). The collection rete of the final
methanol extracts was 23.14 (w/w). Corticosterone was
purchased from Sigma-Aldrich Chemical Co. (St Louis,
MO, USA).
Experimental groups
This study was designed to explore the efficacy of
AGN administration for healing repeated CORT-induced
depression- and anxiety-like behaviors in an animal model
using behavioral and neurobiological methodologies. Differ-
ent groups of rats, seven animals per group, were used for
drug treatment and tests. Doses were calculated as mg/kg
body weight. All the experimental animals including
control and drug-treatment groups were subjected to
administration. The aim of food withdrawn prior to
drug administration was just to ensure the bioavailability
of drug. In other time periods, all animals had free access
to food. The standard dose of AGN in rat was based on
previous study [17]. In addition, considering the long-term
treatment used in the present study, the doses of 10, 20,
50 mg/kg every 24 h were selected. The procedure and
dose of CORT administration was performed as described
in Mao et al. [20]. CORT (40 mg/kg), which was dissolved
in absolute ethanol and subsequently diluted in water to
the final concentration of 10 % ethanol, was administrated
subcutaneously (s.c) in a volume of 1 ml/kg once daily for
21 days [8, 21]. AGN (10, 20, 50 mg/kg) and the positive
drug fluoxetine (15 mg/kg, FLX, Fluoxetine hydrochloride;
Eli Lilly and Company, Basingstoke, Hampshire) were
administered by intraperitoneally (i.p.) in a volume of
10 ml/kg 30 min prior to the CORT injection for 21 days.
This CORT dose was selected because it induces serum
levels of the steroid comparable to those elicited by
substantial stress [22]. As a vehicle control, animal in the
SAL group were subcutaneously given the equivalent
Lee et al. BMC Complementary and Alternative Medicine  (2015) 15:210 Page 2 of 13
volumes in saline to the final concentration of 10 %
ethanol in a volume of 10 ml/kg. The CORT and saline
injections were given in the morning between 9 and
10 am once daily for 21 consecutive days. The SAL group
and CORT group also received saline instead of AGN as a
vehicle control in an equal volume for a period of 21 days.
All drugs were freshly prepared right before every experi-
ment. The following parameters were measured to monitor
the effects of the development of psychosomatic disorders
by exogenous CORT administration: changes of body
weight gains (at the beginning step of exogenous CORT
administration), and serum CORT levels (after repeated
CORT-induced depression- and anxiety-like symptoms).
Sucrose preference test
The sucrose preference test was employed herein to evalu-
ate anhedonia, one of the core symptoms of major depres-
sion in humans. The test was performed as described by
Mao et al. [20]. Before the test, the rats were trained to
adapt to sucrose solution (1 % w/v) by placing two bottles
of sucrose solution in each cage for 24 h prior to the start
of the experiment; then one of the bottles was replaced
with water for 24 h. They were exposed to 1 % sucrose
solution for 24 h period in their home cages without any
food or water available. After the adaptation procedure,
the rats were deprived of water and food for 10 h. The
sucrose preference test was conducted at 10:00 a.m. The
rats were housed in individual cages and given free access
to the two bottles containing 100 mL of sucrose solution
(1 %, w/v) and 100 mL of water, respectively. Sucrose and
water consumption was measured for the period of 3 h
by weighing pre-weighed bottles at the end of the test.
Sucrose preference was measured by calculating the pro-
portion of sucrose consumption out of total consumption
of liquid and was recorded once three days during the
experiment for 21 consecutive days.
Corticosterone (CORT) and brain-derived neurotrophic
factor (BDNF) analysis
After CORT injection for 21 days, CORT concentration
in blood, and BDNF concentration in brain tissue were
determined. Animals were killed by decapitation one day
after behavioral measurements. To avoid fluctuations on
hormone levels due to circadian rhythm, animals were
bled at 12:00-1:00 p.m. on the day of sacrifice. Blood
samples were collected for the determination of serum
CORT levels. For this, the unanesthetized rats were rap-
idly decapitated, and blood was quickly collected via the
abdominal aorta. The hippocampus or medial prefrontal
cortex were rapidly removed from the rat brains in ran-
domized order. Blood was centrifuged at 4000 g for
10 min, and serum was collected and stored at -70 °C
until use. The CORT concentration was measured by a
competitive enzyme-linked immunoassay (ELISA) using
a rabbit polyclonal CORT antibody (Abcam Cortico-
sterone ELISA kit; Cambridge, MA, USA) according to
the manufacturer’s protocol. The brain tissue samples
were stored at -80 °C until use. Hippocampus or medial
prefrontal cortex were homogenized in a lysis buffer con-
taining 137 mM NaCl, 20 mM Tris (pH 8.0), 1 % NP40,
10 % glycerol, 1 mM PMSF, 10 mg/ml aprotinin, 1 mg/ml
leupeptin and 0.5 mM sodium vanadate. Homogenization
was carried out on ice using a tissue homogenizer and in-
cubated for 1 min at 4 °C with shaking. Homogenates
were centrifuged and supernatants were collected. The
BDNF concentration was measured by a competitive
enzyme-linked immunoassay (ELISA) using a mouse
monoclonal BDNF antibody (Novus biologicals BDNF
kit; Novus Biologicals, LLC., Littleton, CO, USA) ac-
cording to the manufacturer’s protocol. Samples (or
standard) and conjugate were added to each well, and
the plate was incubated for 1 h at room temperature
without blocking. After wells were washed several times
with buffers and proper color developed, the optical
density was measured at 450 nm using an ELISA reader
(MutiRead 400; Authos Co., Vienna, Austria).
Forced swimming test (FST)
The FST used was the same as described in detail else-
where [23], with some modification. Briefly, the test was
done by placing a rat in a transparent Plexiglas cylinder
(20 cm diameter × 50 cm height) was filled up to a depth
of 30 cm with water at 25°C. At this depth, rats could
not touch the bottom of the cylinder with their tails or
hind limbs. Two swimming sessions were conducted: an
initial 15 min pretest, followed by a 5 min test 24 h later.
Animals were subjected to 5 min of forced swim, and
escape behaviors (climbing and swimming) were deter-
mined. The animals’ behavior was continuously recorded
by experimenter-manual scoring during the testing session
with an overhead video camera to tape behavior for later
manual scoring. Immobility behavior was calculated as the
length of time in which the animal did not show escape
responses (e.g., total time of the test minus time spent in
climbing and swimming behaviors). The rats were judged
to be immobile when it remained in the water without
struggling and was making only those movements neces-
sary to keep its head above water. Climbing behavior was
defined as upward-directed movements of the forepaws
alone the side of the swim chamber and swimming behav-
ior was considered as movements throughout the swim
chamber including crossing into another quadrant.
Elevated plus maze test (EPM)
The EPM test is a widely used behavioral test to assess
anxiogenic or anxiolytic effects of pharmacological agents.
Animals conduct anxiety-like behaviors usually show the
reductions both in the number of entries and in the time
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spent in the open arms, along with an increase in the
amount of time spent in the closed arms in the EPM. The
elevated plus test was conducted. This apparatus consisted
of two open arms (50 × 10 cm each), two closed arms
(50 × 10 × 20 cm each) and a central platform (10 × 10 cm),
arranged in a way such that the two arms of each type were
opposite to each other. The maze was made from black
Plexiglas and elevated 50 cm above the floor. Exploration of
the open arms was encouraged by testing under indirect
dim light (2 × 60 W). During a 5-min test period, the
following parameters were recorded: 1) number of open
arm entries, b) number of closed arm entries, c) time
spend in open arms, and d) time spent in closed arms.
Entry by an animal into an arm was defined as the con-
dition in which the animal has placed its four paws in
that arm. The behavior in the maze was recorded using
a video camera mounted on the ceiling above the center of
the maze and relayed to the S-MART program (PanLab,
Barcelona, Spain). Anxiety reduction, indicated by open
arm exploration in the EPM, was defined as an increase
in the numbers of entries into the open arms relative to
total entries into either open or closed arm, and an in-
crease in the proportion of time spent in the open arms
relative to total spending time in either open or closed
arm. Total arm entries were also used as indicators of
changes in locomotor activities of the rats.
Open field test (OFT)
Prior to forced swimming test, the rats were individually
housed in a rectangular container that was made of dark
polyethylene (60 × 60 × 30 cm) to provide best contrast
to the white rats in a dimly lit room equipped with a
video camera above the center of the room, and their
locomotion (animal’s movements) and exploratory behavior
were then measured. The locomotion indicated by the time
and the distance of movements was monitored by a com-
puterized video-tracking system using S-MART program
(PanLab Co., Barcelona, Spain). The open field maze was
divided into two zones, central and peripheral zone, using
the square drawn on the maze. The area was divided into
16 squares of 15 × 15 cm by painted white lines. The rats
was placed in one corner of the open filed and its activity
during the subsequent 5 min was assessed. Locomotion
(central zone crossing) and time spent in central and per-
ipheral zone were observed [24].
Immunohistochemistry of corticotropin-releasing factor
(CRF) and tyrosine hydroxylase (TH)
For immunohistochemical studies, the seven rats in each
groups were deeply anesthetized with sodium pentobar-
bital (80 mg/kg, by intraperitoneal injection) and perfused
through the ascending aorta with normal saline (0.9 %)
followed by 300 ml (per rat) of 4 % paraformaldehyde in
0.1 M phosphate-buffered saline (PBS). The brains were
removed in a randomized order, post-fixed over-night, and
cryoprotected with 20 % sucrose in 0.1 M PBS at 4 °C.
Coronal sections 30 μm thick were cut through hypothal-
amus and locus coeruleus (LC) using a cryostat (Leica
CM1850; Leica Microsystems Ltd., Nussloch, Germany).
The sections were immunostained for CRF and TH
expression using the avidin-biotin-peroxidase complex
(ABC) method. Briefly, the sections were incubated
with primary goat anti-CRF antibody (1:500 dilution;
Santa Cruz Biotechnology Inc., California, CA, USA)
and sheep anti-TH antibody (1:2000 dilution; Chemicon
International Inc., Temecular, CA, USA) in PBST (PBS
plus 0.3 % Triton X-100) for 72 h at 4°C. The sections
were incubated for 120 min at room temperature with sec-
ondary antibody. The secondary antibodies were obtained
from Vector Laboratories Co. (Burlingame, CA, USA) and
diluted 1:200 in PBST containing 2 % normal serum. To
visualize immunoreactivity, the sections were incubated
for 90 min in ABC reagent (Vectastain Elite ABC kit;
Vector Labs. Co., Burlingame, CA, USA), and incubated in
a solution containing 3,3′-diaminobenzidine (DAB; Sigma-
Aldrich Chemical Co., St. Louis, MO, USA). Finally, the
tissues were washed in PBS, followed by a brief rinse in
distilled water, and mounted individually onto slides.
Images were captured using the AxioVision 3.0 imaging
system (Carl Zeiss, Inc., Oberkochen, Germany) and
processed using Adobe Photoshop (Adobe Systems, Inc.,
San Jose, CA, USA). The sections were viewed at 200 ×
magnification, and the numbers of CRF and TH labeled
cells was quantified in the hypothalamus and LC. CRF-
and TH-labeled cells were counted by an observer blinded
to the experimental groups. The counted sections were
randomly chosen from equal levels of serial section along
the rostral-caudal axis. The cells within the hypothalamus
and LC areas were counted on each of the five sections
per animal. Counting the immunopositive cells were per-
formed within the square (150 × 150 μm2), anatomically
localized in hypothalamus (Bregma -1.80 mm) and LC
(Bregma -9.96 mm) sections per rat brain according to the
stereotactic rat brain atlas of Paxinos and Watson [25].
Immunohistochemistry analysis of tissue samples from 3
different animals was enough to show the changes of pro-
tein markers at molecular levels, as published in our previ-
ous studies [22]. Distinct brown spots indicating CRF- and
TH-immunopositive cells were observed in the hypothal-
amus and LC. The CRF and TH-immunopositive cells
were only counted when their densities reached a defined
darkness above the background level. The brightness and
contrast of all images were not adjusted to remove any
subjective selection of immunoreactive cells.
Total RNA preparation and RT−PCR analysis
The expression levels of BDNF and TrkB mRNAs were
determined by the reverse transcription-polymerase chain
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reaction (RT-PCR). The brain hippocampus was isolated
from three rats per group. After decapitation, the brain
was quickly removed and stored at -80 °C until use.
The total RNA was prepared from the brain tissue
using a TRIzol® reagent (Invitrogen Co., Carlsbad, CA,
USA) according to the supplier’s instruction. Comple-
mentary DNA was first synthesized from total RNA
using reverse transcriptase (Takara Co., Shiga, Japan).
PCR was performed using a PTC-100 programmable
thermal controller (MJ Research, Inc., Watertown, MA,
USA). The operating conditions were as follows: for
glyceraldehydes-3-phosphate dehydrogenase (GAPDH),
30 cycles of denaturation at 95 °C for 30 s, annealing at
58 °C for 30 s, and extension at 72 °C for 30 s; for BDNF,
27 cycles of denaturation at 95 °C for 30 s, annealing at
57 °C for 30 s, and extension at 72 °C for 30 s; for TrkB,
38 cycles of denaturation at 95 °C for 30 s, annealing at
59 °C for 30 s, and extension at 72 °C for 30 s. All primers
were designed using published mRNA sequences of those
cytokines and a primer designing software, Primer 3, of-
fered by the Whitehead Institute for Biomedical Research
(Cambridge, MA, USA; http://primer3.ut.ee) on the web-
site. The following sequences were used: for GAPDH
(409 bp), (forward) 5′-ATC CCA TCA CCA TCT TCC
AG-3′ and (reverse) 5′-CCT GCT TCA CCA CCT TCT
TG-3′; for BDNF (153 bp), (forward) 5′-CAG GGG CAT
AGA CAA AAG-3′ and (reverse) 5′-CTT CCC CTT
TTA ATG GTC-3′; for TrkB (347 bp), (forward) 5’-TGG
GAC GTT GGG AAT TTG GTT-3’ and (reverse) 5’-CAG
CCG TGG TAC TCC GTG TG-3’. The PCR products
were separated on 1.2 % agarose gels and stained with
ethidium bromide. The density of each band was quanti-
fied using an image-analyzing system (i-Max™, CoreBio
System Co., Seoul, Korea). The expression levels were
compared each other by calculating the relative density of
target band, such as BDNF and TrkB, to that of GAPDH.
Statistical analysis
All measurements were performed by an independent
investigator blinded to the experimental conditions. Re-
sults in figures are expressed as mean ± standard error of
means (SE). Differences within or between normally distrib-
uted data were analyzed by analysis of variance (ANOVA)
using SPSS (Version 13.0; SPSS, Inc., Chicago, IL, USA)
followed by Tukey’s post-hoc test. Statistical significance
was set at p < 0.05.
Results
Effects of AGN on CORT-induced body weight loss, increase
of serum CORT levels and reduction in consumed sucrose
intake
Rats exposed to the repeated administration of exogen-
ous CORT begin to lose body weight on the first day of
CORT injections and this body weight loss is sustained
for a prolonged period of time without restoration and
is even exacerbated in some cases [22]. In the present
study, body weight was evaluated daily for 21 days to
identify whether the repeated administration of CORT
(CORT group) would result in body weight loss (differ-
ence between daily weights and starting weight; Fig. 1a).
Analysis of the body weight values revealed a signifi-
cant gradual reduction of body weight gain over 21 days
in the CORT group relative to control rats (SAL group).
During this period, rats treated with 50 mg/kg AGN ex-
hibited a significant inhibition of the reduction in body
weight gain compared to the CORT group (p < 0.05 on
days 19, 20 and 21). It was that only AGN (50 mg/kg)-
treated group did not show any change in body weight
when compared with the saline-treated group (p = 0.924).
Additionally, the serum CORT levels were measured
in each group following the repeated administration of
CORT for 21 days. ELISA analysis revealed that CORT
administration over 21 days significantly increased serum
CORT concentrations by 193.74 % compared to saline-
treated rats (Fig. 1b; p < 0.05). This indicates that repeated
CORT injections were sufficiently stressful despite the
evoked CORT response (physiological response) to re-
peated CORT injections being significantly greater than
the response to a single CORT injection (data not shown).
In these results, the exogenous CORT-induced depression-
like symptoms were exploited to develop a chronic stress
model in rats. Daily administration of AGN inhibited the
exogenous CORT-induced increase of serum CORT levels
compared to the CORT group (p < 0.05).
In the present study, sucrose preference in rats was ex-
amined once every three days over 21 days to identify
whether the repeated administration of CORT resulted
in differences in the preference of sucrose compared to
saline-treated rats (Fig. 1c). The analysis of sucrose intake
revealed a significant gradual reduction in consumed
sucrose intake over 21 days in the CORT group compared
to the SAL group (p < 0.01 on days 13, 17, 19, and 21;
p < 0.001 on day 15). During this period, rats treated
with 50 mg/kg of AGN exhibited a significant inhibition
of the reduction in consumed sucrose intake compared to
the CORT group (p < 0.01 on day 19; p < 0.05 on day 21).
Fluoxetine, the positive drug, also increased the sucrose
preference in the rat exposed to CORT (p < 0.01 on day
19; p < 0.05 on day 21).
Effects of AGN on CORT-induced depression-like
behaviors
Rats subjected to the repeated administration of exogenous
CORT for 21 days exhibited a significant depression-like
phenotype, characterized by increased an increased dur-
ation of immobility during the FST compared to saline-
treated controls (Fig. 2). Rats in the CORT group exhibited
more immobility during the FST compared to the SAL
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group (p < 0.05; Fig. 2a). Long-term treatment with AGN
(50 mg/kg) for 21 days displayed a significant decrease in
durations of immobility during 5 min in the FST compared
to CORT group (p < 0.05), indicating that the adminis-
tration of 50 of mg/kg AGN decreases depression-like
behaviors. Another key behavior, climbing behavior was
also analyzed. Rats in the CORT group exhibited a sig-
nificant decrease in climbing behavior during the FST
relative to the SAL group (p < 0.01; Fig. 2b). Furthermore,
compared with the CORT group, rats in the CORT +
AGN20 (p < 0.01) and CORT +AGN50 (p < 0.05) groups
exhibited a significant restoration of climbing behavior
time during 5 min in the FST. It was that only AGN
(50 mg/kg)-treated group did not show any change in
immobility time and climbing behavior in the FST when
compared with the saline-treated group (p = 0.513) and
(p = 0.317). This indicates that CORT administration
significantly restores depression-like despair behaviors.
However, repeated administration of exogenous CORT
over 21 days did not induce significant differences in
swimming behaviors among the groups during the FST
(p = 0.988; Fig. 2c). These results reveal that the recovery of
climbing behavior and the reduction in immobility during
depression-like behaviors in the CORT+AGN50 group
were almost comparable to those of the CORT+ FLX
group.
Effects of AGN on CORT-induced anxiety-like behaviors
The effects of AGN administration on anxiety-like behav-
iors, characterized by decreases in open-arm exploration in
the EPM test, were also investigated (Fig. 3). Post hoc com-
parisons revealed a significant decrease in the percentage of
time spent by rats in the open arms of the maze following
the repeated administration of exogenous CORT for 21 days
compared to the saline-treated rats (p < 0.05). However,
compared to the CORT group, rats in the CORT+AGN50
group exhibited a slightly increased restoration of the per-
centage of time spent in open arms of the maze, which was
formerly decreased by CORT-induced anxiety-like behav-
iors, although the findings were only minimally significant
(p = 0.071; Fig. 3a). Similarly, post hoc comparisons re-
vealed a significant decrease in the number of entries into
the open arms of the maze after the repeated administra-
tion of exogenous CORT for 21 days compared to the SAL
group (p < 0.01). Rats in the CORT+AGN50 group also
exhibited a significant restoration in the number of entries
Fig. 1 Effect of AGN administration on body weights gain (a) serum corticosterone levels (b), and sucrose intake (c) of the rats under chronic
CORT injection for 21 consecutive days. *p < 0.05, **p < 0.01, ***p < 0.001 vs. SAL group; #p < 0.05, ##p < 0.01 vs. CORT group
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into the open arms of the maze compared to the CORT
group (p < 0.05; Fig. 3b). It was that only AGN (50 mg/kg)-
treated group did not show any change in open-arm
exploration in the EPM test when compared with the
saline-treated group (p = 0.495) and (p = 0.419). Because
no significant differences appeared in the number of
closed-arm entries between groups in the EPM test, the
observed anxiety-like behaviors of the rats receiving
repeated CORT injections are likely not attributable to
differences in their locomotor activities (p = 0.998; Fig. 4b).
AGN administration without the prior repeated adminis-
tration of exogenous CORT did not elicit anxiolytic or
anxiogenic behavior in this study. These results reveal that
the increase in the number of entries into the open arms
of the maze by the CORT +AGN50 group was almost
comparable to those of the CORT + FLX group.
Effects of AGN on CORT-induced locomotion and exploratory
behaviors
Open-field activity was used to evaluate locomotion and
exploratory behavior among the rats receiving CORT
injections for 21 days (Fig. 4). Rats receiving CORT injec-
tions significantly decreased the time spent in central zone
with corresponding increase in the time spent in the per-
ipheral zone compared to the SAL group (p < 0.05). There
was also significant decrease in central zone crossing
following chronic CORT exposure (p < 0.05). This finding
suggests that CORT-treated rats subsequently produce
exploration activities that are closely associated with
anxiety-like behaviors in the open-field test. However,
AGN-treated rats (50 mg/kg) displayed a significant in-
crease in central zone crossings compared to the CORT
group (p < 0.05), indicating that anxiety-like behaviors
in the CORT + AGN50 group was almost comparable
to those of the CORT + FLX group.
Effects of AGN on CORT-induced CRF- and TH-like
immunoreactivities
Following the behavioral tasks, CRF-like immunoreactivity
was analyzed in the cell bodies of various hypothalamic
regions including the paraventricular nucleus (PVN; Fig. 5a).
The numbers of CRF-immunoreactive fibers in the PVN of
the CORT group were increased by 164.35 %. Analysis of
the numbers of CRF-immunoreactive neurons values
revealed that rats receiving repeated administration of
exogenous CORT exhibited a significant increase of CRF
expression compared to the SAL group (p < 0.05; Fig. 5b).
The number of CRF-immunoreactive neurons was signifi-
cantly decreased in the PVN region of the CORT+AGN50
group compared to the CORTgroup (p < 0.05). This finding
suggests that the increased CRF-immunoreactivity induced
by the repeated administration of exogenous CORT was
significantly restored by AGN administration and that the
number of CRF-immunopositive neurons in the CORT+
AGN50 group was closely associated with that in the
CORT+ FLX group (p < 0.05). TH-like immunoreactivity
was also analyzed in adrenergic regions including the LC
(Fig. 5a). The numbers of TH-immunoreactive fibers in the
LC of the CORT group increased to 192.73 %. Analysis of
the numbers of TH-immunoreactive neurons values re-
vealed that rats repeatedly exposed to exogenous CORT
exhibit a significant increase of TH expression compared
to the SAL group (p < 0.05; Fig. 5c). The number of TH-
immunoreactive neurons significantly decreased in central
Fig. 2 Effect of AGN administration on immobility time (a), climbing
behavior (b) and swimming behavior (c) in forced swimming test
during chronic CORT injection. *p < 0.05, **p < 0.01 vs. SAL group;
#p < 0.05, ##p < 0.01 vs. CORT group
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adrenergic regions of the CORT +AGN50 group relative
to the CORT group (p < 0.05). This finding suggests that
the increased TH-immunoreactivity induced by the re-
peated administration of exogenous CORT was signifi-
cantly restored by AGN administration and that the
number of TH-immunopositive neurons in the CORT+
AGN50 group was closely associated with that in the
CORT + FLX group (p < 0.05).
Effect of AGN on CORT-induced decrease of BDNF levels
in the hippocampus
The ELISA analysis demonstrated that repeated CORT
injection for 21 days significantly decreased the BDNF
concentration in the hippocampus by 31.28 % compared
with rats in the non-treated SAL group. The concentration
of BDNF in the hippocampus was markedly decreased in
the CORT group, as compared to the SAL group (p < 0.05;
Fig. 3 Effect of AGN administration on the percentage of time spent on open and closed arms (a) and the numbers of entries into open and
closed arms (b) in the elevated plus maze during chronic CORT injection. *p < 0.05, **p < 0.01 vs. SAL group; #p < 0.05 vs. CORT group
Fig. 4 Effect of AGN administration on locomotion and exploratory behavior in the open-field test during chronic CORT injection. Representative
photographs are showed the central zone and peripheral zone (a). Change in the central zone crossing (b) and the time spent in central zone (c)
and peripheral zone (d). *p < 0.05 vs. SAL group; #p < 0.05 vs. CORT group
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Fig. 6a). Daily administration of AGN showed significantly
increased the chronic CORT-induced decrease of BDNF
concentration in the hippocampus, as compared to CORT
group (p < 0.05). It also indicated that the concentration of
BDNF in the hippocampus in rats receiving 50 mg/kg
AGN administration was almost compatible with the rats
receiving 10 mg/kg FLX administration.
Effect of AGN on CORT-induced expression of BDNF and
its receptor, TrkB mRNAs in the hippocampus
To investigate the effects of AGN on the mRNAs expres-
sion of BDNF and TrkB, which are two molecules crucial
for antidepressant-like behavior and neurogenesis, we con-
ducted RT-PCR analysis after the CORT administration
for 21 days (Fig. 6b). Hippocampal expression of BDNF
mRNA in the CORT group was significantly decreased
compared with that in the SAL group (p < 0.01). The de-
creased expression of BDNF mRNA in the CORT group
was significantly restored in the CORT +AGN50 group
(p < 0.05). Hippocampal expression of TrkB mRNA in the
CORT group was also significantly decreased compared
with that in the SAL group (p < 0.05). The decreased
expression of TrkB mRNA in the CORT group was signifi-
cantly increased in the CORT +AGN50 group (p < 0.05).
This also indicated that the expression of BDNF mRNA in
the hippocampus in rats receiving 50 mg/kg AGN admin-
istration was closely associated with that in rats receiving
10 mg/kg FLX administration.
Discussion
Previous studies on the emotional effects of chronic CORT
injections in rodents have produced controversial results
[26]. Several studies demonstrated that administration
of the exogenous stress hormone CORT increased the
probability of depression-like behavior in the FST and
tail suspension test (TST), consistent with present results
[8, 9]. GCs also reach the brain, where they exert an
inhibitory influence, halting HPA axis activity through
negative feedback inhibitory regulation [27]. However,
if prolonged stress exists, chronically elevated GC levels
will occur, impairing the negative feedback inhibition, and
finally leading to dysregulated emotional and physiological
homeostasis, which are seen in the etiology of depression
[28]. Thus, the present study suggests that administration
of exogenous CORT may be a useful method for studying
the relationship between stress, behaviors, CORT, neuro-
trophic factors, and depression [29].
Fig. 5 Effects of AGN administration on the mean number of corticotropin-releasing factor (CRF) expression in the paraventricular nucleus (PVN)
of the hypothalamus and tyrosine hydroxylase (TH) expression in the locus coeruleus (LC). Representative photographs and the relative percentage
values are indicated in (a) and (b and c), respectively. *p < 0.01 vs. SAL group; #p < 0.05 vs. CORT group
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Our study is basically intended to test effect of adminis-
tration of AGN on prevention of chronic CORT-induced
depression-like behavior rather the cure. Therefore, in
order to test administration of AGN as the therapeutic
agent for improve depression and anxiety-like symptom in
rats exposed to chronic CORT-induced pathogenesis of
psychologically related disorders, the administration of
AGN was immediately applied before the CORT injection,
and thereby we did examine to evaluate the ability of ad-
ministration of AGN on prevention as measured by their
performance in the FST and the EPM test. Therefore, our
results showed that administration of AGN prior to CORT
injection might be attributable to changes in behavioral
task-related pathways that are modulated by the HPA axis.
Also, an increase in immobility time and reduction of
sucrose preference, which are typically observed in depres-
sion in animal models, might be due to dysregulation of the
HPA axis following the artificial injection of CORT [30].
Sucrose preference reduced, which reflects the symptom
of anhedonia (inability to experience pleasure) existing
in depressed patients, can be improved by antidepressants
[8]. Anhedonia, a core symptom of major depression in
humans, is modeled by inducing a decrease in responsive-
ness to rewards, as reflected by reduced consumption or
preference for sweetened solutions [31]. This theory has
been supported by several studies in which elevated levels
of CORT result in an alteration of HPA axis activity that af-
fected behavioral activity and preference for sucrose [32].
Thus, the present findings revealed that administration of
AGN at 50 mg/kg significantly increased preference for
sucrose and reversed the anhedonic-like behavior, suggest-
ing antidepressant-like actions of AGN.
Furthermore, the current results are consistent with
previous findings showing that repeated CORT injec-
tions increase immobility during the FST [21]. Here, the
administration of AGN significantly decreased immobility
and also increased climbing behaviors during the FST,
but there was no effect on swimming, confirming an
antidepressant-like activity that did not result in motor
function deficits [9, 21]. Our observations of an anxiety-
like behavior in rats following CORT exposure are also
consistent with previous findings [33]. Several studies have
suggested that CORTs are involved in the anxiety-like
features that are frequently seen in psychiatric disorders
such as depression [34, 35]. In the present study, the ad-
ministration of AGN prior to chronic CORT injections
also significantly reduced anxiety-like behaviors in the
EPM test, as indicated by the increase in the number of
entries into open arms. Using a chronic CORT-exposed
rat model, we provided evidence for the anxiolytic-like
potential of AGN, in the EPM test [36]. An open-field
test was also performed to rule out any confounding
motor impairment that can influence outcomes in many
behavioral tests of depression or anxiety [37]. No signifi-
cant individual difference in locomotor activity was ob-
served between groups, suggesting that the administration
of AGN had no effect on sensorimotor performance (data
not shown). However, the administration of AGN prior to
chronic CORT injections significantly reduced anxiety-like
behaviors, as indicated by an increase in the central zone
Fig. 6 Effect of AGN administration on the expression of (BDNF) and TrkB mRNAs (a) and level of BDNF protein concentration (b) in rats
subjected to chronic CORT injection for 21 consecutive days. The expression levels of BDNF and TrkB mRNAs were normalized to that of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA as an internal control. **p < 0.01 vs. the SAL group; #p < 0.05 vs. CORT group
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crossing in the open-field test. Accordingly, these results
suggest that the observed increase in the central zone
crossing in the open-field test was similar to the observed
changes in behavioral performance in the EPM test, which
is likely to be due to anxiolytic activity [25]. Together, the
results obtained from the behavioral studies confirmed
that AGN treatment exerted an antidepressant-like effect
or anxiolytic action in the rats treated with CORT.
When measured immediately after behavioral testing,
a gradual decrease in body weight gain and an increase
in serum CORT levels was observed, indicating that the
chronic CORT injections were sufficiently stressful [22,
38]. It was observed in our study that chronic adminis-
tration of high-dose CORT caused an elevation of serum
CORT levels in the rats, consistent with the previous
studies [39]. Accordingly, in animal models, forced sustain-
ing of high CORT levels can affect animal depression-like
symptoms under experimental conditions, and this might
be associated with the progression or exacerbation of
chronically stressful conditions in humans [39]. Thus,
the present study revealed that the behavioral consequences
of repeated CORT administration were accompanied by
dysregulation of the HPA axis. The administration of AGN
significantly restored body weight and decreased the serum
CORT levels in the late period of AGN administration, sug-
gesting that this therapy inhibited the HPA axis-associated
psychological dysfunction induced by repeated CORT
injections. Our results may help to explain why admin-
istration of AGN affects the hypothalamus in receiving
biochemical and behavioral signals induced by reduced
CORT levels in serum. The current data suggest that
the CRF circuits in the PVN of the hypothalamus are
activated by chronic CORT injections, leading to the
observed depressive- and anxiety-like activity in the behav-
ioral tests [9]. These results show that the administration of
AGN significantly blocks the increase in CRF immunoreac-
tivity in the PVN. This suggests that anti-depressive and
anxiolytic effects following the administration of AGN are
closely associated with CRF modulation in the PVN in the
hypothalamus and activation of the HPA axis [28].
In the present study, TH immunoreactivity in the LC in
response to repeated CORT injections was greater in the
CORT group versus the SAL group. These results are con-
sistent with previous reports that depressive- and anxiety-
like behaviors induced by chronic stress are the result of
alterations in the central noradrenergic system [40]. More-
over, these findings demonstrate that the administration of
AGN significantly reduced TH-like immunoreactivity in
the LC that was previously activated by chronic CORT
injections [41]. Thus, these results suggest that administra-
tion of AGN may indirectly alter catecholamine synthesis
in the brain, producing pharmacological effects [42]. This
would suggest that AGN acts by inhibiting noradrenaline
synthesis in the rat brain and raises the possibility that an
overactive noradrenergic system could contribute to de-
pressive symptomatology, given that the therapeutic action
of antidepressants reverses such overactivity via a decrease
in TH expression in the LC [43]. Thus, the current results
suggest that the central noradrenergic system was involved
in the antidepressant effect of AGN on helpless-like behav-
ior that persists for 21 days in rats administered repeated
CORT injections. Thus, based on the present observations,
a hypothesis concerning the mechanisms underlying the
behavioral effects of AGN can be proposed in which the
depression- and anxiety-induced behaviors occur via
dysregulation of the HPA axis and the neurochemical
interactions between CRF and TH in the brain.
BDNF, an important neurotrophic factor, has also been
implicated in the etiology of major depression and the
mechanism of antidepressant treatment [14]. A clinical
study demonstrated that stress-related psychiatric disor-
ders including depression and anxiety, are associated with
reduced brain BDNF and its receptor TrkB levels [21, 44].
In a recent experiment, chronic social defeat stress or
treatment with exogenous CORT caused a significant
decrease in BDNF expression in the hippocampus, a
brain region that may be related to the pathogenesis of
depression-like symptoms [8, 21, 45]. Thus, BDNF and
TrkB levels may be useful markers for antidepressant-like
response [46]. To determine whether chronic CORT ex-
posure induced changes in BDNF and TrkB expression,
we analyzed BDNF and TrkB mRNAs levels in the hippo-
campus [11]. Consistent with these findings, we found the
3-week CORT injection decreased expression of BDNF and
TrkB mRNAs in the rat hippocampus and depression-like
behavior [21]. Decreased BDNF availability or reduced
levels of the TrkB neurotrophin receptor could reduce
BDNF signaling [47]. However, administration of AGN
restored the level of BDNF and TrkB mRNAs in the
hippocampus of rats subjected to repeated CORT injection,
suggesting that modulation of the BDNF-TrkB neuro-
trophic signaling pathway may play a role in mediating
antidepressant/anxiolytic actions of AGN. Also, the current
results also strongly suggest a close correlation between
protein and gene function in the reduced expression of
BDNF in the hippocampus.
Conclusion
In summary, the results of this study indicate the potential
for AGN to effectively treat CORT-related depression and
anxiety-like symptoms, possibly via modulation of the cen-
tral noradrenergic system and regulation of BDNF expres-
sion. Together, these findings indicate that AGN is capable
of ameliorating the complex behaviors and neurochemical
responses involved in depression by modulating HPA activ-
ity. Accordingly, AGN may be a useful therapeutic agent in
the development of alternative medicines for treating
stress-related disorders such as depression and anxiety.
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